View Older Stories View More Recent Stories

Oct 19, 2017 08:11AM Sunovion Announces Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder is Now Available in the United States
Sep 14, 2017 12:20PM Sunovion’s Aptiom® (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older
Sep 14, 2017 08:00AM Sunovion to Present Data Across Multiple Psychiatric Conditions at the 2017 Psych Congress
Aug 31, 2017 08:00AM Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
Jul 21, 2017 11:30AM Sunovion’s Latuda® (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia
Jul 18, 2017 11:36AM Sunovion Expands Commitment to Building Stronger Communities through Partnerships with the Red Sox Foundation, United Way of Tri-County and Bergen Volunteer Center
Jul 13, 2017 08:00AM Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma
Jun 30, 2017 08:05AM Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda® (lurasidone HCI) for the Treatment of Bipolar Depression in Children and Adolescents
Jun 30, 2017 08:00AM Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for SUN-101/eFlow® (glycopyrrolate) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
May 26, 2017 06:45PM Sunovion Receives Complete Response Letter from FDA for SUN-101/eFlow® (glycopyrrolate) New Drug Application for Chronic Obstructive Pulmonary Disease (COPD)
May 23, 2017 11:00AM Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting
May 23, 2017 09:18AM Sunovion Announces Utibron™ Neohaler® (indacaterol/glycopyrrolate) Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Ch
May 23, 2017 09:15AM Sunovion Presents Phase 3 Data Showing Safety, Efficacy and Improvement in Quality of Life Outcomes in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease Treated with SUN-101/
May 22, 2017 11:00AM Sunovion Announces Positive Results from Study Evaluating Latuda® (lurasidone HCl) in Children and Adolescents with Bipolar Depression at Annual American Psychiatric Association Meeting
May 22, 2017 08:00AM U.S. FDA Accepts for Review Supplemental New Drug Application for Aptiom® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children 4 to 17 Years of Age
May 16, 2017 08:00AM Sunovion Data Presentations at Annual American Psychiatric Association Meeting Showcase Growing Psychiatry Franchise
May 15, 2017 08:15AM Sunovion to Present Clinical Efficacy, Safety and Health-Related Quality of Life Outcomes Data from Its Respiratory Franchise at the American Thoracic Society 2017 International Conference
Apr 21, 2017 11:00AM Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
Apr 19, 2017 08:00AM Sunovion to Present Data on Aptiom® (eslicarbazepine acetate) at the American Academy of Neurology 2017 Annual Meeting
Apr 3, 2017 08:00AM Sunovion Announces Utibron™ Neohaler® (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
Mar 31, 2017 08:00AM Sunovion to Present Data on LATUDA® (lurasidone HCI) at the 25th European Congress of Psychiatry
Mar 13, 2017 09:00AM Sunovion Submits Supplemental New Drug Application to FDA for Use of APTIOM® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children 4 Years of Age and Older
Feb 27, 2017 08:00AM Sunovion Announces Positive Topline Results from Study Evaluating Latuda® (lurasidone HCl) in Children and Adolescents with Bipolar Depression
Feb 22, 2017 08:00AM Demi Lovato, Sunovion and Leading Advocacy Organizations Release Mental Health Documentary as Part of Be Vocal Initiative
Jan 28, 2017 09:30AM Sunovion’s Latuda® (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
Jan 14, 2017 11:31AM Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo
Jan 13, 2017 08:30AM Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
Dec 21, 2016 08:00AM Sunovion Enters into License Agreement for Three Approved Treatment Options for People with COPD in the U.S.
Dec 15, 2016 08:00AM Sunovion Announces Collaboration with AMDA – The Society for Post-Acute and Long-Term Care Medicine
Dec 4, 2016 08:00AM Sunovion to Initiate Recruitment for Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection
Dec 2, 2016 08:00AM Sunovion to Present Data on Latuda® (lurasidone HCl) and Novel Investigational Psychotropic SEP-363856 at the 55th Annual Meeting of the American College of Neuropsychopharmacology
Dec 2, 2016 08:00AM Sunovion Initiates SEP-363856 Phase 2 Program for Patients with Schizophrenia or Parkinson’s Disease Psychosis
Nov 30, 2016 08:00AM Demi Lovato, Sunovion and Leading Advocacy Organizations Launch The Be Vocal Collection in Partnership with Getty Images to Encourage the Realistic Portrayal of Mental Health
Nov 28, 2016 08:01AM Sunovion Presents Clinical and Health Economics Outcome Research Data for Aptiom® (eslicarbazepine acetate) at the American Epilepsy Society (AES) 70th Annual Meeting
Nov 1, 2016 09:30AM Sunovion Recognizes Epilepsy and COPD Awareness Months in the U.S. During November
Oct 27, 2016 08:00AM Sunovion Announces Positive Clinical Study Results for Latuda® (lurasidone HCl) in Adolescents with Schizophrenia
Oct 21, 2016 09:50AM Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics
Oct 20, 2016 10:00AM The American College of Chest Physicians and Sunovion Announce Strategic Initiative Focused on the Importance of Drug Delivery in the Management of COPD
Oct 13, 2016 08:00AM Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow® for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Sep 20, 2016 08:00AM Sunovion Announces Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
Sep 16, 2016 10:54AM Sunovion to Present Data on Latuda® (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
Aug 31, 2016 05:08PM Sunovion Pharma to Acquire Cynapsus Therapeutics (CYNA) in ~$624M Deal
Aug 31, 2016 05:07PM Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
Aug 18, 2016 10:35AM Sunovion Hands On! Annual Community Service Program Contributes More Than 20,000 Employee Volunteer Hours Over Five Years To Support Youth Organizations And Community Relief Efforts
Aug 8, 2016 08:01AM Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda® (lurasidone HCl) in the Treatment of Schizophrenia
Jul 29, 2016 01:28PM Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Jul 22, 2016 08:00AM Sunovion Announces Results of Phase 3 Long-Term Safety Study Showing SUN-101/eFlow® (glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (C
May 23, 2016 08:01AM Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression
May 16, 2016 08:01AM Sunovion Announces Health Outcomes Data on Exacerbation-Related Hospitalizations that Support the Use of Brovana® (arfomoterol tartrate) Inhalation Solution in People with Moderate-to-Severe COPD at
May 15, 2016 01:45PM American Thoracic Society (ATS) and Sunovion Release Landmark Survey of Pulmonologists’ Attitudes and Practices with Inhalation Devices for COPD at the ATS 2016 International Conference
View More Recent Stories View Older Stories